Navigation Links
AGI Dermatics Clinical Data Identifies L-Ergothioneine as Part of Skin's Natural Antioxidant System
Date:2/11/2008

Clinical Data Presented at the 66th Annual Meeting of the American Academy

of Dermatology

FREEPORT, N.Y., Feb. 11 /PRNewswire/ -- New clinical research from AGI Dermatics indicates that L-Ergothioneine (EGT) and its natural receptor, OCTN- 1, are a natural part of the skin's antioxidant defense and are more effective than idebenone in reducing harmful free radicals in photoaged skin. The data was presented at the Poster Session at the 66th Annual Meeting of the American Academy of Dermatology in San Antonio.

"Prior research confirmed that EGT is more effective than idebenone in suppressing MMP-1 secretions that contribute to photodamaged skin," said Daniel Yarosh, PhD, President, AGI Dermatics. "This research tells us that EGT and its receptor are active participants in the skin's natural antioxidant system and have a more significant effect than idebenone in reducing hydroxyl radicals. The findings further underscore the value of EGT in topical skincare formulas that provide benefits in treatment of photoaged skin."

OCTN-1 (Novel Organic Cation Transporter) was recently identified as the receptor for EGT and responsible for its intracellular accumulation. This study of keratinocytes (NHEK) and fibroblasts (NHDF) indicate that the OCTN-1 protein is readily detectable in both skin cell types and suggest that these cells can uptake, store and utilize EGT.

AGI scientists then looked at the influence of EGT and idebenone on UVA340-induced hydrogen peroxide in human fibroblasts. Results show that NHDF treated with EGT had significantly lower levels of damaging hydroxlyl radicals over a 1-hour period than those treated with idebenone.

AGI Dermatics is the developer of Remergent, a doctor-dispensed skincare line based on the science of DNA repair. L-Ergothioneine, an exclusive and maximized amino acid, is formulated in Remergent Clarifying Concentrate2, Progressive Retinol Complex and Advanced Retinol Therapy.

About AGI Dermatics

AGI Dermatics is the bio-pharmaceutical laboratory that has led research of DNA repair of the skin for more than 20 years. Founded by Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology, dedicating research and development to DNA repair, solar impact on the immune system, and cell- signaling in skin. The company's application of groundbreaking active ingredients and meticulously engineered liposome delivery systems is validated in controlled clinical studies and published in dozens of peer-reviewed scientific and medical journals. http://www.agiderm.com


'/>"/>
SOURCE AGI Dermatics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AGI Dermatics President to be Keynote Speaker at the 11th Annual Sunscreen Symposium
2. Contract Services for Big Pharma and Biotechs Driving Growth and Innovation from Discovery to Clinical Trials
3. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
4. Medpace Hires Clinical Pharmacologist, Jim Wei, MD, PhD
5. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
6. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
7. ADVENTRX Announces Consolidation of Clinical and Management Positions
8. Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
9. Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial
10. Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve
11. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample ... the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
Breaking Biology Technology:
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
Breaking Biology News(10 mins):